hide message

Welcome to the Resource Centre

We make it our mission to work with advocates in civil society, business and government to address inequalities of power, seek remedy for abuse, and ensure protection of people and planet.

Both companies and impacted communities thank us for the resources and support we provide.

This is only possible because of your support. Please make a donation today.

Thank you,
Phil Bloomer, Executive Director

Donate now hide message

You are being redirected to the story the piece of content is found in so you can read it in context. Please click the following link if you are not automatically redirected within a couple seconds:

Deal Seeks to Provide Malaria Medicine at Low Prices

Author: Donald McNeil, New York Times, Published on: 18 July 2008

The Clinton Foundation announced Thursday that it had brokered an agreement among several drug makers that it hopes will assure a steady supply of a crucial malaria medicine at reasonable prices for the world’s poor... In 2004, when international donors agreed to pay for artemisinin-based drug cocktails, the price of the raw material soared... Novartis, then the only company with an artemisinin-based drug approved by the World Health Organization, absorbed the losses, and generic drug makers were scared away from the field... The complex deal announced Thursday includes two Chinese suppliers of artemisinin, two Indian companies that process it into derivatives like artesunate, and two more Indian companies, Cipla and Ipca Laboratories, that produce finished pills.

Read the full post here

Related companies: Cipla IPCA Laboratories Novartis